FDA Asks for Input on Device Approval Paperwork
Published Date: 4/10/2026
Notice
Summary
The FDA wants your thoughts on how it collects info for approving new medical devices before they hit the market. This affects device makers who must provide detailed info to prove their products are safe and effective. You’ve got until June 9, 2026, to share your comments, helping shape a smoother, clearer approval process without extra costs or delays.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 4 costs, 1 mixed.
Large Increase in PMA Compliance Hours
If you make Class III medical devices and submit Premarket Approval (PMA) applications, FDA estimates total annual burden for this information collection at 1,182,316 hours. FDA says the overall reporting burden estimate rose by about 244%, driven by more frequent submissions like PMA amendments and 30-day notices.
Pediatric Use Info Must Be Submitted
PMA applicants must provide pediatric-use information under section 515A of the FD&C Act, including a description of pediatric subpopulations and the number of affected pediatric patients. FDA included pediatric information burden in its estimate (pediatric items total 8,306 hours annually).
Recordkeeping Burden for PMA Holders Increased
Applicants with approved PMAs must maintain records used to trace patients and ensure continued safety; FDA estimates 860 active PMAs with recordkeeping averaging 17 hours per recordkeeper for a total of 29,240 hours annually. FDA reports recordkeeping burden rose about 212%.
ClinicalTrials.gov Certification Required (Form FDA 3674)
Certain PMA applications must be accompanied by a certification under 42 U.S.C. 282(j)(5)(B) using Form FDA 3674, and should include National Clinical Trial numbers where available. FDA estimates the annual burden for these certifications at 46 hours total.
Electronic eSTAR Submissions — Setup and Savings
FDA encourages use of the eSTAR electronic submission template. FDA says eSTAR should significantly reduce submission burden, but it included initial eSTAR setup burden in its estimate (9,174 setup submissions at 0.08 hours each, totaling 734 hours annually).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-06905, Clean Air Act Operating Permit Program; Order on Petition for Objection To State Operating Permit for Caerus Piceance, LLC-Hunter Mesa Water Treatment Facility
The EPA said no to a request from an environmental group that wanted to block a pollution permit for Caerus Piceance’s Hunter Mesa water treatment plant in Colorado. This means the plant can keep operating under its current permit, with no new costs or delays. If anyone wants to challenge this decision, they have until June 9, 2026, to take it to court.
Next: 2026-06910, Clean Air Act Operating Permit Program; Order on Petition for Objection to State Operating Permits for Bonanza Creek Energy Operating Company, LLC-Antelope CPF 13-21 Production Facility, State Antelope O-1 Central Production Facility, State North Platte 42-26 Central Production Facility and State Pronghorn 41-32 Central Production Facility
The EPA has decided not to block the air pollution permits for four Bonanza Creek Energy facilities in Colorado after reviewing a petition from an environmental group. This means the company can keep operating under the current permits, but the decision can be challenged in court by June 9, 2026. Local communities and the energy company are the main players affected by this ruling.